U.S. Markets open in 5 hrs 32 mins
  • S&P Futures

    3,789.50
    -4.50 (-0.12%)
     
  • Dow Futures

    30,265.00
    -45.00 (-0.15%)
     
  • Nasdaq Futures

    11,615.75
    -8.00 (-0.07%)
     
  • Russell 2000 Futures

    1,765.80
    -2.20 (-0.12%)
     
  • Crude Oil

    88.20
    +0.44 (+0.50%)
     
  • Gold

    1,732.20
    +11.40 (+0.66%)
     
  • Silver

    20.73
    +0.19 (+0.91%)
     
  • EUR/USD

    0.9921
    -0.0065 (-0.6548%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.71
    -0.36 (-1.24%)
     
  • GBP/USD

    1.1349
    -0.0126 (-1.0985%)
     
  • USD/JPY

    144.5860
    +0.3870 (+0.2684%)
     
  • BTC-USD

    20,234.15
    -25.98 (-0.13%)
     
  • CMC Crypto 200

    459.78
    +1.38 (+0.30%)
     
  • FTSE 100

    7,049.70
    -2.92 (-0.04%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

·1 min read
  • Cara Therapeutics Inc (NASDAQ: CARAannounced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP).

  • Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life.

  • The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress.

  • The presentation includes data from 125 patients with NP and moderate-to-severe pruritus who were randomized to receive oral difelikefalin 2 mg twice daily or a placebo over an 8-week treatment period.

  • The primary efficacy endpoint of change from baseline in the weekly mean of the itch score was achieved (-4.0 difelikefalin vs. -2.4 placebo). A statistically significant reduction in itch intensity was observed with oral difelikefalin at Day 1 compared to placebo, and the effect was maintained through Week 8.

  • A significantly greater proportion of patients achieved a ≥4-point improvement in the itch score at Week 8 with oral difelikefalin vs. placebo (41% difelikefalin vs. 18% placebo, p=0.007).

  • A higher proportion of patients receiving oral difelikefalin vs. placebo achieved a complete response (22% difelikefalin vs. 5% placebo)

  • Oral difelikefalin was generally well tolerated, with all adverse events in difelikefalin-treated patients reported as mild or moderate in severity.

  • Price Action: CARA shares are down 0.27% at $10.93 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.